U.S. markets close in 44 minutes
  • S&P 500

    3,688.48
    +102.86 (+2.87%)
     
  • Dow 30

    29,563.03
    +837.52 (+2.92%)
     
  • Nasdaq

    10,854.83
    +279.21 (+2.64%)
     
  • Russell 2000

    1,715.04
    +50.32 (+3.02%)
     
  • Crude Oil

    83.30
    +3.81 (+4.79%)
     
  • Gold

    1,706.40
    +34.40 (+2.06%)
     
  • Silver

    20.69
    +1.66 (+8.70%)
     
  • EUR/USD

    0.9809
    +0.0008 (+0.08%)
     
  • 10-Yr Bond

    3.6510
    -0.1530 (-4.02%)
     
  • GBP/USD

    1.1302
    +0.0136 (+1.22%)
     
  • USD/JPY

    144.7840
    +0.0550 (+0.04%)
     
  • BTC-USD

    19,539.12
    +227.12 (+1.18%)
     
  • CMC Crypto 200

    443.79
    +8.43 (+1.94%)
     
  • FTSE 100

    6,908.76
    +14.95 (+0.22%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

Antibe Announces Results of 2022 Annual Meeting

·2 min read

TORONTO, September 09, 2022--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the "Meeting") held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the election of directors are provided below:

Director Nominee

Outcome

% For

% Withheld

Robert E. Hoffman

Elected

89.12%

10.88%

Roderick Flower

Elected

94.91%

5.09%

Amal Khouri

Elected

93.51%

6.49%

Dan Legault

Elected

90.14%

9.86%

Walt Macnee

Elected

93.91%

6.09%

Jennifer McNealey

Elected

93.67%

6.33%

John L. Wallace

Elected

94.31%

5.69%

Yung Wu

Elected

94.22%

5.78%

Voting results on all matters voted on at the Meeting have been filed on SEDAR.

About Antibe Therapeutics Inc.
Antibe is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes assets that seek to overcome the gastrointestinal ("GI") ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs ("NSAIDs"). Antibe’s lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today’s NSAIDs for acute pain. Antibe’s second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company’s anticipated next target is inflammatory bowel disease ("IBD"), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005529/en/

Contacts

Antibe Therapeutics Inc.
Christina Cameron
VP Investor Relations
+1 416-577-1443
christina@antibethera.com